Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Mesylate in Recurrent Malignant Gliomas and Meningiomas
NCT00010049Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2001
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in malignant glioma and meningioma (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose and Safety Profile. Started Feb 2001; status: completed.
02
Drugs
03
Conditions
malignant gliomameningioma
Beyond the preview
Go deeper on NCT00010049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010049.